All four major US drug-eluting stent (DES) manufacturers are to work together on an independent, large-scale study designed to investigate the best use of dual antiplatelet therapy (DAPT). As well as Abbott, Boston Scientific, Johnson & Johnson and Medtronic, the trial also involves the US ...
Please Login to read the full article.
